The UC San Diego Goeddel Family Technology Sandbox Now Open
|
MCC's Dr. Uri Manor, recently appointed as Assistant Professor and Faculty Director for the Sandbox, as well as Dr. Arshad Desai, discuss their involvement in and hopes for this unrivaled institution for cutting-edge research and training.
|
Latinx Heritage Month 2024
|
From September 15th through October 2024, join in UC San Diego’s commemoration of Latinx Heritage Month. The theme for the 2024 celebration is "Pioneers of Change: Shaping the Future Together.”
There is a toolkit that includes social media graphics, a Zoom background and other resources to help spread the word and celebrate this heritage month. Additionally, on October 17th, Executive Director of the California Student Aid Commission, Dr. Daisy Gonzales, will deliver a keynote presentation.
|
Moores Member Awarded SMB Leah Edelstein-Keshet Prize
|
MCC's Dr. Kathleen Curtius received the Society for Mathematical Biology’s Leah Edelstein-Keshet Prize! This award is given to someone with a track record of exceptional scientific contributions to mathematical biology and exemplifies a high level of both scientific endeavor and leadership. Congratulations Dr. Curtius.
|
Moores Member Highlighted in Nature Medicine for Breast Cancer Breakthrough
|
Moores member Dr. Rebecca Shatsky has been highlighted for her work with datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Her work has been published in Nature Medicine, and is to be presented at ESMO Congress 2024.
|
Solid Tumor Therapeutics 2024 Retreat
|
Join program leaders and members to discuss the future directions of the Solid Tumor Therapeutics program and help plan for the Moores Cancer Center CCSG renewal. The retreat will take place on Thursday, September 26, 2024 from 9:00 a.m. to 3:30 p.m. with a networking reception to follow.
|
|
|
Measuring Toxicity in Reproductive Organs During Oncology Drug Development
|
Join the Federal Drug Administration (FDA) & the American Society for Clinical Oncology (ASCO) for a free virtual workshop on October 1 & 8, 2024. Moores Member Dr. Irene Su will discuss how advances in cancer care must consider the impact on patients' reproductive health.
|
Moores to Co-host Delivering Discoveries: Updates in Oncology CME
|
Faculty from UC San Diego and SDSU, among others, will present the latest cancer research to improve patient outcomes, spanning all aspects of cancer, from basic science and clinical advances to community-based prevention and interception strategies.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
American Cancer Society Virtual Funding Forum |
You are invited to join CFR on Thursday, September 19 at 1:00 p.m. for their virtual funding forum focusing on the American Cancer Society’s current funding opportunities, including the Research Scholar Grants, Clinician Scientist Development Grant, Discovery Boost Grants, Mission Boost Grants, and the Leukemia Exploration and Prevention Grant Program. This forum will review the application guidelines for early-career, mid-career and experienced researchers for these grant programs.
During the forum you can connect with the CFR team, ask questions, and learn about the application process. Please reach out to us here (CFR@ucsd.edu) with any questions.
|
Deadline - October 5, 2024
Award $ | Period - Budget not limited | 5 years
|
Deadline - February 5, 2025
Award $ | Period - $ 500,000/per year | 5 years
|
|
|
| The genomic landscape of 2,023 colorectal cancers
|
Ludmil B. Alexandrov, PhD (Structural & Functional Genomics)
|
|
|
| Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells
|
Dan Kaufman, MD, PhD (Hematologic Malignancies)
|
|
|
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
|
Rafael Bejar, MD, PhD (Hematologic Malignancies)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
BGB-11417-301: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB11417) Plus Zanubrutinib (BGB3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia |
PI: Benjamin Heyman, MD
NCT: NCT06073821
|
| |
|
